Otofonix Encore vs Otofonix Groove

The Otofonix Encore is a budget-priced prescription hearing aid available for $295, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This behind-the-ear device ranks #37 of 39 in the Prescription Hearing Aid category, placing it in the bottom tier of its class. In our standardized testing, the Encore demonstrates one clear strength: excellent feedback handling at 4.7/5, which means users are unlikely to experience whistling or squealing during normal use. However, the device shows significant limitations in other areas. Speech intelligibility scores are low in both quiet (1.0/5) and noisy environments (1.0/5), falling 2.40 and 1.11 points below category averages respectively. Music streaming performance scored 0.0/5, indicating this device is not suitable for those who want to stream audio content. The Encore uses disposable batteries and comes in a traditional behind-the-ear style. Notably, our tuned fit testing showed a slight decrease in overall performance compared to the initial fit, with the normalized score dropping from 2.8/5 to 2.4/5. Own-voice comfort also declined substantially when moving to a more occluding coupling. At this price point, consumers may want to consider alternatives. The RxEars Rxi offers substantially better performance at a similar budget price point with a score of 4.07/5. The Otofonix Encore may appeal to buyers seeking a very low-cost entry into prescription hearing aids who prioritize feedback stability, but those needing reliable speech clarity or streaming capabilities should explore other options.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.